Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Labor Relations and Union-Management Negotiation Experts (US)

Analysis of: Velcade (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma (www.therapeuticsdaily.com)
Velcade, given with Melphalan & Prednisone approved for use 1st line in non-transplant myeloma patients first line.
Analysis of: Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study (jco.ascopubs.org)
2 separate studies show that: 1. "...there was no statistically significant difference in overall survival....for gefitinib compared with docetaxel. Gefitinib remains an effective treatment option for previously treated Japanese patients with NSCLC." http://jco.ascopubs.org/cgi/content/full/26/26/4244...
Stephen Fugale, Chief Information Officer
Stephen Fugale, Chief Information Officer
Villanova University In The State of Pennsylvania
Analysis of: Dell Plans to Sell Factories (online.wsj.com)
The move is important as Dell seeks to improve results. Is the location and ownership of factories important (as part of the supply chain management) for the company? Will Dell suffer product quality issues?
Analysis of: In Long-Awaited Maps of Cancer, The Breakthrough Is the Problem (online.wsj.com)
Pharmacogenomics will lead to the development of targeting agents and offer true hope for the future.
Adam Fein, PhD, Founder & President
Adam Fein, PhD, Founder & President
Pembroke Consulting Inc
Analysis of: Drug Stores Don’t See Progress for Electronic Drug-Pedigree Bill (fdanews.com)
Representatives Steve Buyer (R-IN), Gene Green (D-TX), Jim Matheson (D-UT), and Mike Rogers (R-MI) co-sponsored H.R. 5839 Safeguarding America’s Pharmaceuticals Act of 2008. H.R. 5839 was going to be incorporated into other related FDA legislation, but intense behind-the scenes lobbying by the pharmacy...
Analysis of: MTNL inks CDMA deal with IOL Netcom (www.business-standard.com)
MTNL CDMA (Garuda) has been a loosing business. IOL Netcom has now been roped in as franchisee to compete with Garuda and others in Delhi and Mumbai. Gains of economies of scale and customer intra-network usage incentives, as achieved in pan India CDMA networks of RCom and TataTeleservices, are not...
Adam Fein, PhD, Founder & President
Adam Fein, PhD, Founder & President
Pembroke Consulting Inc
Analysis of: Bill to track medicines is praised (www.signonsandiego.com)
Implementation of California’s e-pedigree law has (probably) been pushed back to 2015. The widespread industry support for the bill makes me believe that the 2015 date might actually stick. The more realistic timeline should encourage pharmaceutical manufacturers to get serious about mass serialization...
Analysis of: Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery (www.therapeuticsdaily.com)
Novartis is looking for approval for therapy in C-KIT + Gastrointestinal stromal tumors
Analysis of: BPL appoints advisors for Loop stake sale (www.business-standard.com)
Having acquired 2G licenses at low prices ($400 million for pan India license and spectrum), companies like Datacom Solutions, Unitech, Loop Telecom and Swan Telecom are seeking enterprize valuations of $ 2-3 billion dollars while offering majority stakes to foreign Telcos. With more than 10 service...
Analysis of: Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents (jco.ascopubs.org)
Bcl-2 inhibition by small molecules stands to be the next avenue for antineoplastic therapy- Looks like the real deal!

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next61 to 70 of 672

Analytics


Generated at 2009-01-07T19:00:58.307